Patterns of Recurrence and Clinical Outcome of Patients With Stage IIIC to Stage IV Epithelial Ovarian Cancer in Complete Response After Primary Debulking Surgery Plus Chemotherapy or Neoadjuvant Chemotherapy Followed by Interval Debulking Surgery: An Italian Multicenter Retrospective Study.

Angiolo Gadducci, Stefania Cosio, Valentina Zizioli, Sara Notaro, Roberta Tana, Andrea Panattoni, Enrico Sartori
{"title":"Patterns of Recurrence and Clinical Outcome of Patients With Stage IIIC to Stage IV Epithelial Ovarian Cancer in Complete Response After Primary Debulking Surgery Plus Chemotherapy or Neoadjuvant Chemotherapy Followed by Interval Debulking Surgery: An Italian Multicenter Retrospective Study.","authors":"Angiolo Gadducci, Stefania Cosio, Valentina Zizioli, Sara Notaro, Roberta Tana, Andrea Panattoni, Enrico Sartori","doi":"10.1097/IGC.0000000000000843","DOIUrl":null,"url":null,"abstract":"<p><strong>Objective: </strong>The objective of this retrospective study was to assess the clinical outcome of patients with advanced epithelial ovarian cancer in complete response after primary debulking surgery (PDS) or neoadjuvant chemotherapy followed by interval debulking surgery (IDS]).</p><p><strong>Methods: </strong>The authors reviewed the hospital records of 384 patients who underwent PDS (n = 322) or IDS (n = 62) and who were in complete response after primary treatment.</p><p><strong>Results: </strong>Optimal (residual disease [RD] < 1 cm) and complete (no gross RD) cytoreduction rates were higher after IDS than after PDS (71.0% vs 55.9%; P = 0.001 and 51.6% vs 35.7%, respectively; P = 0.02). Tumor recurred in 73.0% of the 322 complete responders after PDS versus 87.1% of the 62 complete responders after IDS (P = 0.01). The IDS group showed a higher recurrence rate within 6 months (11.3% vs 3.1%: P = 0.01) and a trend to higher recurrence rate between 6 and 12 months (30.6% vs 19.9%). Tumor recurred in 57.4% of the 115 completely cytoreduced patients after PDS versus 87.5% of the 32 completely cytoreduced patients after IDS (P = 0.001). The IDS group showed a trend to higher recurrence rate within 6 months (6.2% vs 1.7%) and a higher recurrence rate between 6 and 12 months (37.5% vs 15.6%; P = 0.01). Two-year, 5-year, and 7-year progression-free survival were 65.8%, 40.8%, and 39.3% for completely cytoreduced patients after PDS versus 43.8%, 12.5%, and 12.5% for completely cytoreduced patients after IDS (P = 0.001); and 2-year, 5-year, and 7-year overall survival were 96.4%, 69.3%, and 50.4% for the former versus 87.1%, 41.8%, and 32.6% for the latter (P = 0.001).</p><p><strong>Conclusions: </strong>The clinical outcome of completely cytoreduced patients was significantly better for PDS group than for IDS group, and therefore, the achievement of no gross RD after surgery seemed to have a different prognostic relevance for the 2 groups.</p>","PeriodicalId":13983,"journal":{"name":"International Journal of Gynecologic Cancer","volume":"30 1","pages":"28-36"},"PeriodicalIF":0.0000,"publicationDate":"2017-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"International Journal of Gynecologic Cancer","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1097/IGC.0000000000000843","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

Objective: The objective of this retrospective study was to assess the clinical outcome of patients with advanced epithelial ovarian cancer in complete response after primary debulking surgery (PDS) or neoadjuvant chemotherapy followed by interval debulking surgery (IDS]).

Methods: The authors reviewed the hospital records of 384 patients who underwent PDS (n = 322) or IDS (n = 62) and who were in complete response after primary treatment.

Results: Optimal (residual disease [RD] < 1 cm) and complete (no gross RD) cytoreduction rates were higher after IDS than after PDS (71.0% vs 55.9%; P = 0.001 and 51.6% vs 35.7%, respectively; P = 0.02). Tumor recurred in 73.0% of the 322 complete responders after PDS versus 87.1% of the 62 complete responders after IDS (P = 0.01). The IDS group showed a higher recurrence rate within 6 months (11.3% vs 3.1%: P = 0.01) and a trend to higher recurrence rate between 6 and 12 months (30.6% vs 19.9%). Tumor recurred in 57.4% of the 115 completely cytoreduced patients after PDS versus 87.5% of the 32 completely cytoreduced patients after IDS (P = 0.001). The IDS group showed a trend to higher recurrence rate within 6 months (6.2% vs 1.7%) and a higher recurrence rate between 6 and 12 months (37.5% vs 15.6%; P = 0.01). Two-year, 5-year, and 7-year progression-free survival were 65.8%, 40.8%, and 39.3% for completely cytoreduced patients after PDS versus 43.8%, 12.5%, and 12.5% for completely cytoreduced patients after IDS (P = 0.001); and 2-year, 5-year, and 7-year overall survival were 96.4%, 69.3%, and 50.4% for the former versus 87.1%, 41.8%, and 32.6% for the latter (P = 0.001).

Conclusions: The clinical outcome of completely cytoreduced patients was significantly better for PDS group than for IDS group, and therefore, the achievement of no gross RD after surgery seemed to have a different prognostic relevance for the 2 groups.

一项意大利多中心回顾性研究:IIIC至IV期上皮性卵巢癌患者在初次减体积手术加化疗或新辅助化疗后间隔减体积手术后完全缓解的复发模式和临床结果
目的:本回顾性研究的目的是评估晚期上皮性卵巢癌患者在初次减瘤手术(PDS)或新辅助化疗后间隔减瘤手术(IDS)后完全缓解的临床结果。方法:作者回顾了384例经初步治疗后完全缓解的PDS (n = 322)或IDS (n = 62)患者的医院记录。结果:IDS后最佳(残留病变[RD] < 1 cm)和完全(无总RD)细胞减少率高于PDS后(71.0% vs 55.9%;P = 0.001, 51.6% vs 35.7%;P = 0.02)。322例PDS完全缓解者肿瘤复发率为73.0%,而62例IDS完全缓解者肿瘤复发率为87.1% (P = 0.01)。IDS组6个月内复发率较高(11.3% vs 3.1%, P = 0.01), 6 ~ 12个月复发率有升高趋势(30.6% vs 19.9%)。115例完全细胞减少的PDS患者中有57.4%的肿瘤复发,而32例完全细胞减少的IDS患者中有87.5%的肿瘤复发(P = 0.001)。IDS组6个月内复发率较高(6.2% vs 1.7%), 6 ~ 12个月复发率较高(37.5% vs 15.6%;P = 0.01)。PDS后完全细胞减少患者的2年、5年和7年无进展生存率分别为65.8%、40.8%和39.3%,而IDS后完全细胞减少患者的2年、5年和7年无进展生存率分别为43.8%、12.5%和12.5% (P = 0.001);前者的2年、5年和7年总生存率分别为96.4%、69.3%和50.4%,后者为87.1%、41.8%和32.6% (P = 0.001)。结论:PDS组完全细胞减少患者的临床结局明显好于IDS组,因此,术后无总RD的实现似乎与两组的预后有不同的相关性。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信
小红书